Bristol-Myers Squibb

Showing 11 posts of 146 posts found.

Blood clot fears halt cancer trial enrolment

February 3, 2011
Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer

Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …

NICE decides to back Abilify in schizophrenia

January 27, 2011
Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia

NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …

BMS and Sanofi recall 64 million Avalide tablets

January 18, 2011
Manufacturing and Production Avalide, Avapro, Bristol-Myers Squibb, GMP, Good Manufacturing Practice, Sanofi-Aventis, hypertension, irbesartan

Bristol-Myers Squibb and Sanofi-Aventis have started another massive recall of their antihypertensive product Avalide because a manufacturing defect could affect …


BMS appoints Dr Veronique Walsh

January 5, 2011
Sales and Marketing BMS, Bristol-Myers Squibb, Dr Véronique Walsh, appointment, sales and marketing

Bristol-Myers Squibb UK has appointed Dr Véronique Walsh as business unit director, neuroscience and immunoscience . She joins the company …

VTE trial boost for Pfizer and BMS’ apixaban

December 31, 2010
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism

Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …

BMS licences phase II HIV compound festinavir

December 22, 2010
Research and Development BMS, Bristol-Myers Squibb, HIV, NRTI, Oncolys BioPharma, festinavir, nucleoside reverse transcriptase inhibitor

Bristol-Myers Squibb is to pay hundreds of millions of dollars to a Japanese biotech firm to get its hands on …

Bristol-Myers Squibb appoints new UK general manager

December 13, 2010
Manufacturing and Production, Research and Development, Sales and Marketing Amadou Diarra, BMS, Bristol-Myers Squibb, appointment, recruitment, sales and marketing

Bristol-Myers Squibb has appointed Amadou Diarra as general manager of its UK company, where he will be in charge of …

NICE limits access to cancer drugs, study confirms

November 10, 2010
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, hta

NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests. The …

Advanced melanoma

BMS skin cancer drug hits US regulatory delay

November 3, 2010
Research and Development BMS, Bristol-Myers Squibb, FDA, MDX010-020 trial, ipilimumab, skin cancer

US regulators have announced they need more time to assess Bristol-Myers Squibb’s skin cancer treatment ipilimumab. The FDA will not …

BMS faces approval block unless GMP issues are resolved

November 2, 2010
Manufacturing and Production BMS, Bristol-Myers Squibb, FDA, Puerto Rico, belatacept, manufacturing compliance, pharma manufacturing

Bristol-Myers Squibb has been threatened with a block on approvals of certain new drugs, including a biologic for preventing organ …

Pharma manufacturing news in brief

October 26, 2010
Manufacturing and Production AMRI, BASF, BMS, Bend Research, Bristol-Myers Squibb, Parmetics, Stirling Pharma, Vical, pharma manufacturing

This week’s round-up of pharmaceutical manufacturing news features updates from Pharmetics, AMRI, Bend Research/BMS, Stirling Pharma, Vical and BASF. A …

Latest content